source
- Boehringer targets 2027 submission of obesity drug survodutide after positive cardiovascular trialBoehringer Ingelheim announced that its experimental obesity therapy survodutide is moving toward regulatory filing. The move follows the drug's successful phase 3 cardiovascular outcomes study, w…
- Experts warn US Treasury's biotech investment ban on China could backfireThe U.S. Treasury released a draft policy to implement the Comprehensive Outbound Investment National Security (COINS) Act, proposing to add pharmaceutical compounds to an outbound investment black…